ABEONA THERAPEUTICS Business Summary

Abeona Therapeutics Inc. (ABEO) is a commercial-stage biopharmaceutical company specializing in the development and delivery of autologous cell and gene therapies for life-threatening rare genetic diseases. The company’s primary revenue model is centered on the commercial sale of its lead product, ZEVASKYN® (prademagene zamikeracel or pz-cel), which received FDA approval in April 2025 as the first autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa (RDEB). Revenue is recognized upon clinical application at specialized Qualified Treatment Centers (QTCs), supported by a permanent CMS J-code that went into effect on January 1, 2026. Additionally, the company leverages non-dilutive capital through the sale of its Rare Pediatric Disease Priority Review Voucher (PRV). In the competitive landscape, Abeona contends with Krystal Biotech, Savara Inc., and Sana Biotechnology; however, it distinguishes itself as the only provider of a single-application, cell-based corrective sheet therapy, positioning it as a premium surgical alternative to topical gene therapies. Abeona is led by President and CEO Dr. Vishwas (Vish) Seshadri, who previously spearheaded the global launch of the CAR-T therapy Breyanzi at Celgene and Bristol Myers Squibb. The executive suite includes CFO Joseph Vazzano, Chief Commercial Officer Madhav Vasanthavada—another Celgene veteran with extensive cell therapy launch experience—and Senior VP and Chief Business Officer Mohamad Tabrizi, a seasoned venture capitalist and former investment banker appointed in late 2025. The Board of Directors is chaired by Michael Amoroso, the company's former CEO and current head of Precision BioSciences. Abeona maintains a strong institutional backing with notable investors including Sco Capital Partners, Adage Capital Management, and Nantahala Capital Management, reflecting high confidence in the company’s transition from a clinical-stage developer to a profitable commercial entity in 2026.